Compare Crispr Therapeutics AG (CRSP) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Global X Defense Tech ETF — how do they compare? Crispr Therapeutics AG trades at $51.3 (market cap $4.88B), while Global X Defense Tech ETF trades at $59.16 (market cap $6.29B). The key difference: Global X Defense Tech ETF is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Global X Defense Tech ETF for 44 Days on average.
| CRSP | SHLD | |
|---|---|---|
Market Cap | $4.88B | $6.29B |
Volume | 2,861,747 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $74.92 | $78.02 |
52-Week Low | $44.34 | $58.20 |
Typical Hold Time | 77 Days | 44 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
SHLD, the Global X Defense Tech ETF, trades at $58.74, down 2.2% on the day amid a bearish technical signal. The ETF focuses on defense technology and cybersecurity, with recent institutional buying interest noted in filings. However, key financial ratios like P/E and P/S are not available for this ETF, and the overall technical picture is negative, with moving averages and oscillators signaling bearish momentum.
The outlook for SHLD is mixed, with potential tailwinds from rising global defense spending and institutional accumulation, but weighed down by bearish technicals and the absence of clear valuation metrics. Risks include geopolitical shifts and ETF-specific performance versus peers. The investment case hinges on sustained defense budget growth and SHLD's ability to capture tech-driven defense innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
